-
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:02:11ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T CellsDaiichi Sankyo2023-11-09 21:01:48Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated
-
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:01:36ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020Daiichi Sankyo2023-11-09 21:01:17Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with
-
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal CancerDaiichi Sankyo2020-09-15 15:08:35Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced
-
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual MeetingDaiichi Sankyo2023-11-09 20:59:40Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be
-
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical careDaiichi Sankyo2020-09-01 10:19:50New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and
-
NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during 2.5 years of treatmentDaiichi Sankyo2023-11-09 20:59:16NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during
-
ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights important clinical considerations for treating elderly patients with atrial fibrillationDaiichi Sankyo2023-11-09 20:59:05ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights
-
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062Daiichi Sankyo2020-08-03 09:16:13Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi
